This Article Full Text Full Text (PDF) All Versions of this Article: 19/1/76    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by De Vita, G. Articles by Di Lauro, R. Search for Related Content PubMed PubMed Citation Articles by De Vita, G. Articles by Di Lauro, R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB TAMOXIFEN THYROGLOBULIN

Dose-Dependent Inhibition of Thyroid Differentiation by RAS Oncogenes

Stazione Zoologica Anton Dohrn, 80121 Napoli, Italy

Address all correspondence and requests for reprints to: Roberto Di Lauro, Stazione Zoologica Anton Dohrn, Villa Comunale 1, 80121 Napoli, Italy. E-mail: dilauro{at}szn.it.

Activating mutations in RAS protooncogenes are associated with several different histotypes of thyroid cancer, including anaplastic thyroid carcinoma. The latter is the most aggressive cancer of the thyroid gland, showing little or no expression of the differentiated phenotype. Likewise, expression of viral RAS oncogenes in FRTL-5 rat thyroid cells mimics such loss of differentiation. We established FRTL-5 cell lines stably expressing constitutively active forms of RAS, either of viral (v-Ha-RAS or v-Ki-RAS) or cellular (H-RAS^V12) origin and generated a tamoxifen-inducible RAS oncoprotein to analyze the timing of RAS effects on thyroid differentiation. In RAS-transformed FRTL-5 cells, we measured the expression of many thyroid-specific genes by real-time PCR and observed that a clear loss of differentiation was only obtained in the presence of high RAS oncogene expression. In contrast, TSH-independent growth appeared to be induced in the presence of both low and high levels of oncogenic RAS expression. We also showed that inhibition of differentiation is an early RAS-induced phenomenon. Finally, we demonstrated that only high doses of RAS oncogenes are able to inhibit the activity of Titf1 and Pax8, two transcription factors essential for the maintenance of thyroid differentiation, and that the homeodomain of Titf1 is a target of the inhibitory action of RAS. Our results represent the first evidence of a dose- dependent effect of RAS oncogenes on thyroid epithelial differentiation.

This article has been cited by other articles:

				G. Riesco-Eizaguirre and P. Santisteban New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy Endocr. Relat. Cancer, December 1, 2007; 14(4): 957 - 977. [Abstract] [Full Text] [PDF]

				B. D'Andrea, R. Iacone, T. Di Palma, R. Nitsch, M. G. Baratta, L. Nitsch, R. Di Lauro, and M. Zannini Functional Inactivation of the Transcription Factor Pax8 through Oligomerization Chain Reaction Mol. Endocrinol., August 1, 2006; 20(8): 1810 - 1824. [Abstract] [Full Text] [PDF]

				C. Garcia-Jimenez, M. A. Zaballos, and P. Santisteban DARPP-32 (Dopamine and 3',5'-Cyclic Adenosine Monophosphate-Regulated Neuronal Phosphoprotein) Is Essential for the Maintenance of Thyroid Differentiation Mol. Endocrinol., December 1, 2005; 19(12): 3060 - 3072. [Abstract] [Full Text] [PDF]